| Patient | Diagnosis | Response | Type I IFN activity in sera, before treatment | Type I IFN activity in sera, after treatment p = 0.037 | MxA expression in muscle tissue, before treatment | MxA expression in muscle tissue, after treatment p = 0.05 |
| 1 | PM | Improved | 2.55 | 0 | 3.9 | 0.64 |
| 2 | PM | Improved | 0.0 | 0.11 | 0.24 | 0.64 |
| 3 | PM | Worse | 0.0 | 0.38 | 0.03 | 2.05 |
| 4 | PM | Worse | 1.38 | 4.06 | 0.15 | 0.24 |
| 5 | PM | Dropped out | 7.17 | 8.85 | NA | NA |
| 6 | DM | Unchanged | 0.2 | 11.8 | 0.16 | 0.4 |
| 7 | DM | Dropped out | NA | NA | NA | NA |
| 8 | DM | Dropped out | NA | NA | NA | NA |
| 9 | DM | Dropped out/worse | NA | NA | NA | NA |
| 10 | IBM | Improved | 0 | 3.9 | 1.33 | 0.9 |
| 11 | IBM | Unchanged | 4.03 | 4.44 | 0.37 | 0.56 |
| 12 | IBM | Unchanged | 0 | 5.3 | 1.35 | 3.14 |
| 13 | IBM | Unchanged | 0.05 | 0 | NA | NA |
DM, dermatomyositis; IBM, inclusion body myositis; PM, polymyositis; MxA, intracellular antiviral protein (a marker for IFNα) expression in muscle tissue; NA, not analysed.